JAC Advance Access originally published online on March 31, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2004) 53, 783-792
© 2004 The British Society for Antimicrobial Chemotherapy
Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492
Department of Medical Microbiology, City Hospital NHS Trust, Dudley Road, Birmingham B18 7QH, UK
Received 18 April 2003; returned 18 July 2003; revised 4 February 2004; accepted 11 February 2004
Objectives: The in vitro activity of a new fluoroquinolone, ABT-492, was determined.
Methods: MICs were compared with those of two ß-lactams, telithromycin, ciprofloxacin and four later generation fluoroquinolones. The effects of human serum and of inoculum concentration were also investigated.
Results: MIC data indicate that ABT-492 has potent activity against Gram-positive organisms with enhanced anti-staphylococcal activity compared with earlier fluoroquinolones, in addition to activity against ß-haemolytic streptococci, pneumococci including penicillin- and fluoroquinolone-resistant strains and vancomycin-susceptible and -resistant Enterococcus faecalis but not Enterococcus faecium. ABT-492 was the most active agent tested against Haemophilus influenzae, Moraxella catarrhalis, Neisseria meningitidis, fluoroquinolone-susceptible Neisseria gonorrhoeae and anaerobes. Good activity was observed for ABT-492 amongst the Enterobacteriaceae and anaerobes tested, but ciprofloxacin showed superior activity for species of Proteus, Morganella and Providencia, as well as for Pseudomonas spp. In common with the other fluoroquinolones tested, organisms with reduced susceptibility to ciprofloxacin had raised MIC90s to ABT-492. The one isolate of H. influenzae tested with reduced fluoroquinolone susceptibility had an ABT-492 MIC close to that of the population lacking a mechanism of quinolone resistance. ABT-492 was more active than ciprofloxacin against Chlamydia spp. An inoculum effect was observed with a number of isolates of Staphylococcus aureus, Streptococcus pneumoniae, E. faecium, Klebsiella spp. and Escherichia coli, in addition to moderately raised MICs in the presence of 70% serum protein. The clinical significance of these findings is yet to be determined.
Conclusions: ABT-492 is a new fluoroquinolone with excellent activity against both Gram-positive and Gram-negative organisms, with many potential clinical uses.
Keywords: antibacterials, bacterial resistance, quinolones
* Corresponding author. Tel: +44-121-507-4825; Fax +44-121-551-7763; E-mail: adam.fraise{at}swbh.nhs.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. D. Hermsen, L. B. Hovde, K. A. Sprandel, K. A. Rodvold, and J. C. Rotschafer Levofloxacin plus Metronidazole Administered Once Daily versus Moxifloxacin Monotherapy against a Mixed Infection of Escherichia coli and Bacteroides fragilis in an In Vitro Pharmacodynamic Model Antimicrob. Agents Chemother., February 1, 2005; 49(2): 685 - 689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Hammerschlag and P. M. Roblin The in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniae J. Antimicrob. Chemother., July 1, 2004; 54(1): 281 - 282. [Full Text] [PDF]
|
|